Alzheimer's disease drug development pipeline: 2021.

Cummings, Jeffrey; Lee, Garam; Zhong, Kate; Fonseca, Jorge; Taghva, Kazem

Cummings, Jeffrey; Lee, Garam; Zhong, Kate; Fonseca, Jorge; Taghva, Kazem.

Afiliação

Cummings J; Chambers-Grundy Center for Transformative Neuroscience Department of Brain Health School of Allied Health Sciences, University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
Lee G; Biogen Weston Massachusetts USA.
Zhong K; Department of Brain Health School of Allied Health Sciences University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
Fonseca J; Howard R. Hughes College of Engineering Department of Computer Science University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
Taghva K; Howard R. Hughes College of Engineering Department of Computer Science University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.

Alzheimers Dement (N Y) ; 7(1): e12179, 2021.

Article em En | MEDLINE | ID: mdl-34095440

Palavras-chave

Alzheimer's disease; Common Alzheimer's Disease Research Ontology (CADRO); National Institutes of Health; amyloid; biomarkers; clinical trials; drug development; inflammation; pharmaceutical companies; repurposed drugs; tau

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Alzheimers Dement (N Y) Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Alzheimers Dement (N Y) Ano de publicação: 2021 Tipo de documento: Article